Non-Alcoholic Fatty Liver Disease and Bone Tissue Metabolism: Current Findings and Future Perspectives.

Oxana M Drapkina, Anastasia Yu Elkina, Anna F Sheptulina, Anton R Kiselev
Author Information
  1. Oxana M Drapkina: Department of Fundamental and Applied Aspects of Obesity, National Medical Research Center for Therapy and Preventive Medicine, 101990 Moscow, Russia. ORCID
  2. Anastasia Yu Elkina: Department of Intermediate Level Therapy, Saratov State Medical University, 410012 Saratov, Russia.
  3. Anna F Sheptulina: Department of Fundamental and Applied Aspects of Obesity, National Medical Research Center for Therapy and Preventive Medicine, 101990 Moscow, Russia. ORCID
  4. Anton R Kiselev: Coordinating Center for Fundamental Research, National Medical Research Center for Therapy and Preventive Medicine, 101990 Moscow, Russia. ORCID

Abstract

Non-alcoholic fatty liver disease (NAFLD) is reaching epidemic proportions worldwide. Moreover, the prevalence of this liver disease is expected to increase rapidly in the near future, aligning with the rise in obesity and the aging of the population. The pathogenesis of NAFLD is considered to be complex and to include the interaction between genetic, metabolic, inflammatory, and environmental factors. It is now well documented that NAFLD is linked to the other conditions common to insulin resistance, such as abnormal lipid levels, metabolic syndrome, and type 2 diabetes mellitus. Additionally, it is considered that the insulin resistance may be one of the main mechanisms determining the disturbances in both bone tissue metabolism and skeletal muscles quality and functions in patients with NAFLD. To date, the association between NAFLD and osteoporosis has been described in several studies, though it worth noting that most of them included postmenopausal women or elderly patients and originated from Asia. However, taking into account the health and economic burdens of NAFLD, and the increasing prevalence of obesity in children and adolescents worldwide, further investigation of the relationship between osteopenia, osteoporosis and sarcopenia in NAFLD, including in young and middle-aged patients, is of great importance. In addition, this will help to justify active screening and surveillance of osteopenia and osteoporosis in patients with NAFLD. In this review, we will discuss various pathophysiological mechanisms and possible biologically active molecules that may interplay between NAFLD and bone tissue metabolism.

Keywords

References

  1. Fibrogenesis Tissue Repair. 2010 Apr 01;3(1):5 [PMID: 20359335]
  2. Int J Mol Sci. 2022 Jul 27;23(15): [PMID: 35955431]
  3. Clin Sci (Lond). 2019 Feb 12;133(3):465-481 [PMID: 30755499]
  4. Hepatology. 2021 Apr;73(4):1594-1608 [PMID: 32986864]
  5. Dis Markers. 2010;29(5):213-21 [PMID: 21206006]
  6. Pharmaceutics. 2020 May 21;12(5): [PMID: 32455750]
  7. JHEP Rep. 2022 Aug 23;5(1):100563 [PMID: 36644237]
  8. Dig Liver Dis. 2017 Jun;49(6):618-622 [PMID: 28274829]
  9. Int J Oncol. 2019 Feb;54(2):420-430 [PMID: 30535434]
  10. J Am Soc Nephrol. 2018 Apr;29(4):1108-1127 [PMID: 29330340]
  11. Int J Med Sci. 2016 Jan 01;13(1):25-38 [PMID: 26816492]
  12. Chem Biol Interact. 2018 Jun 1;289:109-118 [PMID: 29738702]
  13. Exp Cell Res. 2005 Sep 10;309(1):99-109 [PMID: 15963981]
  14. J Clin Endocrinol Metab. 1994 Sep;79(3):775-9 [PMID: 8077360]
  15. J Zhejiang Univ Sci B. 2023 Mar 15;24(3):248-261 [PMID: 36916000]
  16. Front Microbiol. 2023 Feb 02;14:1117644 [PMID: 36819064]
  17. Front Endocrinol (Lausanne). 2021 Mar 31;12:599339 [PMID: 33868162]
  18. J Inflamm Res. 2019 Apr 26;12:99-108 [PMID: 31118735]
  19. Nutrients. 2019 Jul 25;11(8): [PMID: 31349604]
  20. J Biol Chem. 2015 Feb 27;290(9):5533-42 [PMID: 25575598]
  21. Front Cell Dev Biol. 2023 Feb 21;11:1104709 [PMID: 36895792]
  22. Nat Commun. 2020 Nov 26;11(1):5997 [PMID: 33244003]
  23. Int J Endocrinol. 2018 Jul 29;2018:2314769 [PMID: 30151008]
  24. Int J Behav Nutr Phys Act. 2020 Nov 26;17(1):150 [PMID: 33239014]
  25. Cancers (Basel). 2020 Nov 15;12(11): [PMID: 33203146]
  26. Nature. 2013 Nov 28;503(7477):493-9 [PMID: 24172895]
  27. Endocr J. 2017 Jul 28;64(7):663-673 [PMID: 28539530]
  28. Metabolism. 2003 Oct;52(10):1274-8 [PMID: 14564678]
  29. Ital J Pediatr. 2019 Dec 10;45(1):161 [PMID: 31823791]
  30. Eur J Endocrinol. 2014 Mar 08;170(4):547-53 [PMID: 24412930]
  31. Int J Environ Res Public Health. 2021 May 14;18(10): [PMID: 34069012]
  32. Biochim Biophys Acta Mol Basis Dis. 2018 Mar;1864(3):700-708 [PMID: 29237572]
  33. Dig Dis Sci. 2023 Feb;68(2):644-655 [PMID: 35672623]
  34. Cells. 2021 Jul 19;10(7): [PMID: 34359989]
  35. Exp Ther Med. 2022 May 26;24(1):470 [PMID: 35747145]
  36. Int J Mol Sci. 2023 Mar 08;24(6): [PMID: 36982235]
  37. Cureus. 2023 Feb 13;15(2):e34921 [PMID: 36938188]
  38. Eur J Endocrinol. 2020 Feb;182(2):157-164 [PMID: 31770104]
  39. J Nutr Biochem. 2004 Jun;15(6):350-7 [PMID: 15157941]
  40. Nutrients. 2021 Nov 23;13(12): [PMID: 34959747]
  41. Ther Apher Dial. 2018 Oct;22(5):519-529 [PMID: 29974642]
  42. Poult Sci. 2022 Apr;101(4):101708 [PMID: 35150940]
  43. Scand J Clin Lab Invest. 2018 Feb - Apr;78(1-2):125-130 [PMID: 29272979]
  44. Front Endocrinol (Lausanne). 2023 Feb 24;14:1077604 [PMID: 36909330]
  45. Zhonghua Gan Zang Bing Za Zhi. 2016 Feb;24(2):96-101 [PMID: 26983475]
  46. JHEP Rep. 2022 Apr 04;4(6):100482 [PMID: 35540106]
  47. Int J Environ Res Public Health. 2019 Sep 14;16(18): [PMID: 31540048]
  48. Front Endocrinol (Lausanne). 2023 Jan 13;13:1100063 [PMID: 36714568]
  49. Front Endocrinol (Lausanne). 2022 Oct 25;13:990667 [PMID: 36387843]
  50. Hepatology. 2019 Sep;70(3):812-823 [PMID: 30706504]
  51. Clin Liver Dis (Hoboken). 2020 Sep 04;16(2):73-76 [PMID: 32922754]
  52. Osteoporos Int. 2022 Nov;33(11):2275-2286 [PMID: 35764892]
  53. Curr Hepatol Rep. 2016 Jun;15(2):75-85 [PMID: 27218012]
  54. Gut Liver. 2020 Mar 15;14(2):168-178 [PMID: 31195434]
  55. Medicine (Baltimore). 2018 Oct;97(42):e12835 [PMID: 30334985]
  56. Cureus. 2021 Dec 28;13(12):e20776 [PMID: 35111461]
  57. Front Endocrinol (Lausanne). 2019 Nov 22;10:815 [PMID: 31824428]
  58. Intern Med. 2020 May 15;59(10):1247-1256 [PMID: 32101831]
  59. Front Cell Infect Microbiol. 2022 Jul 04;12:821429 [PMID: 35860378]
  60. Antioxidants (Basel). 2023 Feb 03;12(2): [PMID: 36829932]
  61. Int J Endocrinol Metab. 2020 Jul 07;18(3):e97205 [PMID: 33257903]
  62. J Mol Histol. 2023 Apr;54(2):119-134 [PMID: 36930413]
  63. Nutrients. 2018 Apr 16;10(4): [PMID: 29659559]
  64. Wei Sheng Yan Jiu. 2022 Nov;51(6):926-933 [PMID: 36539869]
  65. Gene. 2022 Apr 5;817:146192 [PMID: 35031425]
  66. Lab Invest. 2013 Oct;93(10):1082-9 [PMID: 23999249]
  67. Clin Liver Dis. 2018 Feb;22(1):133-140 [PMID: 29128053]
  68. Front Endocrinol (Lausanne). 2020 Oct 23;11:585689 [PMID: 33193098]
  69. Calcif Tissue Int. 2023 Feb;112(2):126-147 [PMID: 35305134]
  70. Diabetes Metab Syndr Obes. 2020 Oct 13;13:3667-3690 [PMID: 33116718]
  71. Cells. 2019 Aug 02;8(8): [PMID: 31382483]
  72. FASEB J. 1993 Dec;7(15):1475-82 [PMID: 8262332]
  73. Ter Arkh. 2022 Feb 15;94(2):216-253 [PMID: 36286746]
  74. Best Pract Res Clin Endocrinol Metab. 2018 Oct;32(5):725-738 [PMID: 30449551]
  75. Int J Clin Exp Med. 2015 Oct 15;8(10):17221-34 [PMID: 26770315]
  76. Nat Commun. 2020 Nov 16;11(1):5807 [PMID: 33199780]
  77. Drug Des Devel Ther. 2021 Nov 23;15:4741-4757 [PMID: 34848946]
  78. J Taibah Univ Med Sci. 2023 Jan 28;18(5):917-925 [PMID: 36852342]
  79. Int J Mol Sci. 2023 Feb 02;24(3): [PMID: 36769264]
  80. J Nutr Biochem. 2018 Sep;59:93-103 [PMID: 29986312]
  81. Int J Mol Sci. 2022 May 19;23(10): [PMID: 35628490]
  82. Front Cardiovasc Med. 2022 Apr 25;9:824561 [PMID: 35548441]
  83. Curr Issues Mol Biol. 2023 Jan 05;45(1):479-489 [PMID: 36661517]
  84. Front Endocrinol (Lausanne). 2020 Jan 28;10:926 [PMID: 32063885]
  85. Nutrients. 2019 Jun 21;11(6): [PMID: 31234301]
  86. J Clin Med. 2023 Jan 05;12(2): [PMID: 36675380]
  87. Front Endocrinol (Lausanne). 2022 Oct 28;13:1012508 [PMID: 36387862]
  88. BMC Endocr Disord. 2022 Mar 14;22(1):63 [PMID: 35287643]
  89. Food Funct. 2021 Feb 15;12(3):963-975 [PMID: 33443523]
  90. Sci Rep. 2021 Oct 6;11(1):19883 [PMID: 34615940]
  91. Immun Ageing. 2019 Jul 10;16:15 [PMID: 31333751]
  92. Eur J Clin Invest. 2021 Mar;51(3):e13403 [PMID: 32918277]
  93. Cureus. 2021 Apr 13;13(4):e14479 [PMID: 33996337]
  94. Sci Rep. 2020 Nov 16;10(1):19837 [PMID: 33199796]
  95. Nutrients. 2022 Oct 07;14(19): [PMID: 36235815]
  96. Med Sci Monit. 2020 Jan 30;26:e919159 [PMID: 31996665]
  97. J Clin Med. 2020 Dec 26;10(1): [PMID: 33375318]
  98. Immunity. 2020 Sep 15;53(3):641-657.e14 [PMID: 32888418]
  99. Biomedicines. 2018 May 07;6(2): [PMID: 29735928]
  100. J Prev Med Public Health. 2020 Sep;53(5):342-352 [PMID: 33070506]
  101. Sci Rep. 2022 May 16;12(1):8090 [PMID: 35577842]
  102. Gene Expr. 2018 May 18;18(2):89-101 [PMID: 29212576]
  103. Microbiologyopen. 2019 Aug;8(8):e00810 [PMID: 31001921]
  104. PLoS One. 2014 Oct 13;9(10):e110405 [PMID: 25310107]
  105. Aging Cell. 2020 Aug;19(8):e13183 [PMID: 32638492]
  106. J Diabetes Res. 2020 Aug 10;2020:6191468 [PMID: 32851096]
  107. Obes Surg. 2016 Oct;26(10):2425-32 [PMID: 26989059]
  108. Biomed Pharmacother. 2020 Jan;121:109566 [PMID: 31698268]
  109. FASEB J. 2021 Jul;35(7):e21740 [PMID: 34143911]
  110. Ann Hepatol. 2020 Jul - Aug;19(4):344-352 [PMID: 32005637]
  111. World J Hepatol. 2018 Jan 27;10(1):142-154 [PMID: 29399288]

Grants

  1. 23-45-10030/Russian Science Foundation

MeSH Term

Middle Aged
Adolescent
Child
Humans
Female
Aged
Non-alcoholic Fatty Liver Disease
Diabetes Mellitus, Type 2
Insulin Resistance
Pediatric Obesity
Bone and Bones
Osteoporosis
Risk Factors

Word Cloud

Created with Highcharts 10.0.0NAFLDpatientsosteoporosisliverdiseasebonetissuemetabolismfattyworldwideprevalenceobesityconsideredmetabolicinsulinresistancemaymechanismsosteopeniawillactiveNon-alcoholicreachingepidemicproportionsMoreoverexpectedincreaserapidlynearfuturealigningriseagingpopulationpathogenesiscomplexincludeinteractiongeneticinflammatoryenvironmentalfactorsnowwelldocumentedlinkedconditionscommonabnormallipidlevelssyndrometype2diabetesmellitusAdditionallyonemaindeterminingdisturbancesskeletalmusclesqualityfunctionsdateassociationdescribedseveralstudiesthoughworthnotingincludedpostmenopausalwomenelderlyoriginatedAsiaHowevertakingaccounthealtheconomicburdensincreasingchildrenadolescentsinvestigationrelationshipsarcopeniaincludingyoungmiddle-agedgreatimportanceadditionhelpjustifyscreeningsurveillancereviewdiscussvariouspathophysiologicalpossiblebiologicallymoleculesinterplayNon-AlcoholicFattyLiverDiseaseBoneTissueMetabolism:CurrentFindingsFuturePerspectivesnon-alcoholic

Similar Articles

Cited By